Skip to main content
. 2021 Dec 16;43(10):959–967. doi: 10.1093/eurheartj/ehab836

Figure 3.

Figure 3

Ranking of treatments according to P-scores for each outcome. Coloured bars show the surface under the cumulative ranking curve values for each endpoint. Higher bars correspond to higher surface under the cumulative ranking curve and indicate better performing treatments. P-scores range between 0 and 1: the higher the P-score value, the higher the likelihood that a therapy is more effective or safe. major adverse cardiovascular events: 1° = guided (0.931), 2° = prasugrel (0.673), 3° = clopidogrel (0.199), and 4° = ticagrelor (0.198); all bleeding: 1° = clopidogrel (0.983), 2° = guided (0.569), 3° = prasugrel (0.233), and 4° = ticagrelor (0.214); all death: 1° = guided (0.764), 2° = ticagrelor (0.756), 3° = prasugrel (0.411), and 4° = clopidogrel (0.069); cardiovascular death: 1° = ticagrelor (0.771), 2° = guided (0.650), 3° = prasugrel (0.512), and 4° = clopidogrel (0.066); myocardial infarction: 1° = guided (0.983), 2° = prasugrel (0.669), 3° = ticagrelor (0.337), and 4° = clopidogrel (0.011); stent thrombosis: 1° = prasugrel (0.930), 2° = guided (0.633), 3° = ticagrelor (0.428), and 4° = clopidogrel (0.009); stroke: 1° = guided (0.891), 2° = prasugrel (0.574), 3° = clopidogrel (0.472), and 4° = ticagrelor (0.063); major bleeding: 1° = clopidogrel (0.779), 2° = guided (0.701), 3° = ticagrelor (0.413), and 4° = prasugrel (0.088); minor bleeding: 1° = clopidogrel (0.889), 2° = guided (0.776), 3° = ticagrelor (0.200), and 4° = prasugrel (0.136). *, best treatment.